{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T15:37:46Z","timestamp":1768837066710,"version":"3.49.0"},"reference-count":24,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,11,24]],"date-time":"2014-11-24T00:00:00Z","timestamp":1416787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2015,2]]},"abstract":"<jats:p>The optimal treatment strategy with the use of hematopoietic stem cell transplantation (HSCT) for relapsed and refractory Hodgkin lymphoma (HL) remains unclear. We performed a retrospective analysis using registry data from the Japanese Society for Hematopoietic Cell Transplantation. Adult patients with HL who underwent a first autologous or a first allogeneic HSCT between 2002 and 2009 were included. Patients who underwent HSCT in first complete remission (CR) were excluded. Autologous and allogeneic HSCT were performed in 298 and 122 patients, respectively. For autologous HSCT, overall survival at 3 years (3yOS) was 70%, and sex, age, disease status, and performance status (PS) at HSCT were prognostic factors. OS was favorable even in patients who underwent autologous HSCT in disease status other than CR. For allogeneic HSCT, 3yOS was 43%, and sex and PS at HSCT were prognostic factors. Disease status at HSCT, previous autologous HSCT, and conditioning intensity did not affect OS. Moreover, graft\u2010versus\u2010host disease did not affect progression\u2010free survival or relapse\/progression rate. A first allogeneic HSCT without a previous autologous HSCT was performed in 40 patients. 3yOS was 45%, and was significantly inferior to that in patients who underwent their first autologous HSCT. This result was retained after the correction by the different patient characteristics according to the type of HSCT. In conclusion, autologous HSCT is effective in prolonging survival in patients with relapsed and refractory HL. Allogeneic HSCT might be beneficial even to relapsed HL after autologous HSCT, although establishing the role of allogeneic HSCT remains a challenge. Am. J. Hematol. 90:132\u2013138, 2015. \u00a9 2014 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23897","type":"journal-article","created":{"date-parts":[[2014,11,10]],"date-time":"2014-11-10T09:11:36Z","timestamp":1415610696000},"page":"132-138","source":"Crossref","is-referenced-by-count":13,"title":["The role of hematopoietic stem cell transplantation for relapsed and refractory <scp>H<\/scp>odgkin lymphoma"],"prefix":"10.1002","volume":"90","author":[{"given":"Shinichi","family":"Kako","sequence":"first","affiliation":[{"name":"Division of Hematology Saitama Medical Center Jichi Medical University Saitama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[{"name":"Department of Hematology Toranomon Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science Kyushu University Graduate School of Medical Sciences Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung\u2010Won","family":"Kim","sequence":"additional","affiliation":[{"name":"Hematopoietic Stem Cell Transplantation Division National Cancer Center Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiko","family":"Mori","sequence":"additional","affiliation":[{"name":"Division of Hematology Keio University School of Medicine Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Hematopoietic Stem Cell Transplantation Division National Cancer Center Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology Sapporo Hokuyu Hospital Hokkaido Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Taji","sequence":"additional","affiliation":[{"name":"Hematology and Cell Therapy Aichi Cancer Center Hospital Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisako","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Hematology Clinical Immunology, Kobe City Medical Center General Hospital\/Department of Cell Therapy, Institute of Biomedical Research and Innovation Hyogo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadakazu","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Graduate School of Medicine, Kyoto University Kyoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Sakamaki","sequence":"additional","affiliation":[{"name":"Hematology Division Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Morishima","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Prevention Aichi Cancer Center Research Institute Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Children's Medical Center, Japanese Red Cross Nagoya First Hospital Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritsuro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation Data Management and Biostatistics Nagoya University School of Medicine Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Suzumiya","sequence":"additional","affiliation":[{"name":"Cancer Center, Shimane University Hospital Shimane Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the Adult Lymphoma Working Group of the Japanese Society for Hematopoietic Cell Transplantation","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,11,24]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/asheducation.V2012.1.313.3797303","article-title":"Point\/counterpoint: Early\u2010stage Hodgkin lymphoma and the role of radiation therapy","volume":"2012","author":"Meyer RM","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.497"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3101"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.3.814"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8419"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03006932"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)00006-0"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.103"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.5.1395"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh304"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705977"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13441"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.11.011"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.080895"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.2415"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392104"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.23.4314"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-253856"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-418673"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-397893"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23897","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T09:13:22Z","timestamp":1696583602000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,24]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.1002\/ajh.23897"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23897","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,24]]}}}